North America’s pharma industry saw a rise of 5.9% in deal activity during April 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 90 pharma industry deals worth $5.73bn were announced for the region in April 2019, against the 12-month average of 85 deals.
Of all the deal types, venture financing saw most activity in April 2019 with 60 transactions, representing a 66.7% share for the region.
In second place was M&A with 21 deals, followed by private equity deals with nine transactions, respectively capturing a 23.3% and 10% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s pharma industry with $3.35bn, while private equity and venture financing deals totalled $1.26bn and $1.13bn, respectively.
North America pharma industry deals in April 2019: Top deals
The top five pharma deals accounted for 74.6% of the overall value during April 2019.
The combined value of the top five pharma deals stood at $4.28bn, against the overall value of $5.73bn recorded for the month. The top announced pharma deal tracked by GlobalData in April 2019 was Novartis ‘ $1.58bn acquisition of IFM Tre .
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.